Understanding interpatient variation of clinical responses among acute lymphoblastic leukaemia (All) patients treated with 6-mercaptopurine (6-Mp): a pharmacogenomics-metabolomics perspective / Wan Rosalina Wan Rosli
Leukaemia chemotherapy had advanced considerably, enabling higher rates of survival and cure. This success is largely attributable to optimization of the use of chemotherapeutic agents such as 6-mercaptopurine (6-MP). However challenges still remain in striking a delicate balance between therapeutic...
Main Author: | Wan Rosli, Wan Rosalina |
---|---|
Format: | Book Section |
Language: | English |
Published: |
Institute of Graduate Studies, UiTM
2012
|
Subjects: | |
Online Access: | https://ir.uitm.edu.my/id/eprint/19123/1/ABS_WAN%20ROSALINA%20WAN%20ROSLI%20TDRA%20VOL%201%20IGS%2012.pdf |
Similar Items
-
The differential metabolite profiles of acute lymphoblastic leukaemic patients treated with 6-mercaptopurine using untargeted metabolomics approach
by: Bannur, Zakaria, et al.
Published: (2014) -
An ICMPv6 threat model / Wan Nor Ashiqin Wan Ali
by: Wan Ali, Wan Nor Ashiqin
Published: (2015) -
Cytotoxicity effect of 6-mercaptopurine and 6-mercaptopurine riboside on RAW 264.7 and HIG-82 cell lines
by: Che Ku Daud, Che Ku Dahlan, et al.
Published: (2014) -
Anaerobiospirillum succiniciproducens bacteraemia in a patient with acute lymphoblastic leukaemia
by: Fadzilah, M.N., et al.
Published: (2009) -
Severe asymptomatic hypophosphataemia in a child with T-acute lymphoblastic leukaemia
by: Zakaria, N.H., et al.
Published: (2017)